HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population

Lamotrigine (LTG) was first synthesized in the early 1980s and approved by the US Food and Drug Administration in 1994. Since then, it has been used worldwide as an effective anticonvulsant and as a mood stabilizer. However, LTG can cause adverse reactions including cutaneous adverse drug reactions with approximately 10% probability.1 Severe cutaneous adverse reactions (SCARs) are the most serious form and include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS).

http://ift.tt/2noc6pE